Foundation Medicine is a company within the Healthcare & Biotechnology category. Foundation Medicine is a molecular information company that provides comprehensive genomic profiling (CGP) to identify the unique molecular signatures of a patient's cancer. Their technology assists physicians in matching patients with targeted therapies, immunotherapies, and clinical trials based on the specific genomic alterations found in the tumor.
Foundation Medicine was founded in 2010 and is headquartered in Cambridge, MA.
Foundation Medicine is rated Leader on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Foundation Medicine is Moderate. Significant factual deltas detected.
AI models classify Foundation Medicine as a Challenger. AI names competitors first.
Foundation Medicine appeared in 7 of 8 sampled buyer-intent queries (88%). Foundation Medicine dominates high-intent branded and scientific queries but faces heavy competition from 'liquid biopsy' and 'cancer genetic testing' queries where startups and SEO-focused labs compete for AI preference.
AI will reliably portray the brand as a scientific authority and pioneer in precision oncology. It maintains high accuracy regarding product names and ownership, though it may lag on the most recent therapeutic companion diagnostic approvals. Key gap: AI often focuses on its historical role as a Cambridge startup rather than its current deep integration as a core pillar of Roche's global personalized healthcare strategy.
Of 5 key facts verified about Foundation Medicine, 4 are well-documented (likely accurate across AI models), 0 have limited sourcing, and 1 are retrieval-dependent and may be inaccurate without live search.
Specifics of real-world evidence (RWE) data partnerships and the exact scale of their genomic database, which changes rapidly.
Buyers turn to Foundation Medicine for Standard of Care Pathology: Using traditional tissue biopsy and standard pathology reports without comprehensive genomic profiling., Fragmented Single-Gene Testing: Coordinating with multiple specialized labs for individual gene tests rather than a single comprehensive panel., Traditional Clinical Trial Matching: Physicians relying on historical clinical data and intuition for treatment selection rather than personalized molecular insights., among 3 documented problem areas.
Buyers evaluating Foundation Medicine typically ask AI models about "What is comprehensive genomic profiling?", "FDA approved companion diagnostics for lung cancer", "best liquid biopsy for solid tumors", and 1 similar queries.
Foundation Medicine's main competitors are Guardant Health, GRAIL. According to AI models, these are the brands most frequently named alongside Foundation Medicine in buyer-intent queries.
Foundation Medicine's core products are Comprehensive Genomic Profiling (FoundationOne CDx, FoundationOne Liquid CDx, FoundationOne Heme) and data/research services..
Foundation Medicine uses Insurance-based/Enterprise/Custom.
Foundation Medicine serves Oncologists, Cancer Centers, Pharmaceutical Companies, Clinical Researchers.
Foundation Medicine The first company to receive FDA approval for a broad companion diagnostic test for all solid tumors.
Brand Authority Index (BAI) tier: Leader (exact score locked for unclaimed brands)
Archetype: Challenger
https://optimly.ai/brand/foundation-medicine
Last analyzed: April 10, 2026
Founded: 2010
Headquarters: Cambridge, MA